Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Safety and Efficacy of RVL-1201 in the Treatment of Acquired Blepharoptosis

Trial Profile

A Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Safety and Efficacy of RVL-1201 in the Treatment of Acquired Blepharoptosis

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 18 Sep 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Oxymetazoline (Primary)
  • Indications Blepharoptosis
  • Focus Therapeutic Use
  • Sponsors Osmotica Pharmaceutical; RevitaLid
  • Most Recent Events

    • 18 Sep 2019 According to a Vertical Pharmaceuticals media release, results will be presented at Ophthalmology Innovation Summit (OIS@AAO 2019), American Society of Ophthalmic Plastic and Reconstructive Surgery (ASOPRS) Fall Scientific Symposium 2019, American Academy of Optometry (AAOptom) Academy Conference 2019, Academy of Managed Care Pharmacy (AMCP) Nexus 2019 and 16th annual American Academy of Aesthetic Medicine (AAAM) Congress 2019.
    • 07 May 2019 Status changed from recruiting to completed.
    • 10 Feb 2019 Planned End Date changed from 28 Dec 2018 to 28 Feb 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top